Clinical Trial Update: Reversal of Dabigatran Anticoagulant Effect With Idarucizumab [Phase 3]

View source ↗

Summary

Phase 3 clinical trial updating on reversal of dabigatran anticoagulant effect using idarucizumab.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemorrhage

Drugs mentioned

• Dabigatran (Dabigatran etexilate)
• Idarucizumab (idarucizumab)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Hemorrhage | Phase 3 | Status: COMPLETED | Results posted: 2017-08-18